Related Experiment Video

Updated: Aug 26, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic stroke patients treated with

Yu Yan1, Ruixiao Hao1, Xiuyuan Zhao1

  • 1Department of Neurology, Tianjin Medical University Second Hospital, Tianjin, China.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|October 10, 2022
PubMed

Insights

CYP2C19*2 gene variants and poor CYP2C19 metabolism increase stroke recurrence risk in patients treated with clopidogrel. Carriers of CYP2C19*2 and *3 are more prone to recurrent strokes than CYP2C19*1 carriers.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Genetics

Background:

  • The association between CYP2C19 gene variants (*2, *3) and clopidogrel efficacy in ischemic stroke patients remains debated.
  • This study aimed to clarify the correlation between CYP2C19 *2,*3 genotypes, metabolic status, and stroke recurrence.

Approach:

  • A comprehensive meta-analysis was conducted, including 9 articles with 10 trials and 1333 ischemic stroke patients.
  • Literature search spanned major databases (CNKI, Wanfang, VIP, CBM, PubMed, Cochrane) up to December 2020.
  • Meta-analysis was performed using RevMan 5.3 software.

Key Points:

  • CYP2C19*2 GA/AA genotypes significantly elevated recurrent stroke risk compared to GG (OR=2.50, 95% CI: 1.66–3.75).
  • Poor metabolizers (PM) and intermediate metabolizers (IM) of CYP2C19 showed a higher risk of recurrent stroke than extensive metabolizers (EM).
  • No significant difference in recurrence risk was observed for CYP2C19*3 GA vs. GG genotype.

Conclusions:

  • CYP2C19*2 gene mutations and altered CYP2C19 metabolism are linked to increased stroke recurrence in patients on clopidogrel.
  • Individuals carrying CYP2C19*2 and *3 variants face a higher likelihood of recurrent stroke compared to CYP2C19*1 carriers.
Abstract

Keywords:
CYP2C19 variantClopidogrelIschemic strokeMeta-analysisRecurrence

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

826
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
615
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
282
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
23